Preconditioning Drug Offers Potential to Reduce Side Effects of Cardiac Surgery

After enduring cardiopulmonary bypass, many patients experience an inflammatory response, which can lead to prolonged ventilation, bleeding, stroke, and renal dysfunction. The NewYork-Presbyterian and Weill Cornell Medicine trial center was chosen to further investigate RBT-1 to see if it can help the production of anti-inflammatory cytokines and reduce the occurrence of common post-surgical complications. Researchers found that patients who received RBT-1 had a 46 percent decrease in blood product transfusions, a lower likelihood of readmission to the hospital within 30 days, and spent less time in the ICU and on a ventilator.